Valvular heart disease is a major cause of morbidity and mortality worldwide. Surgical valve repair or replacement has been the standard of care for patients with valvular heart disease for many decades, but transcatheter heart valve therapy has revolutionized the field in the past 15 years. However, despite the tremendous technical evolution of transcatheter heart valves, to date, the clinically available heart valve prostheses for surgical and transcatheter replacement have considerable limitations. The design of next-generation tissue-engineered heart valves (TEHVs) with repair, remodelling and regenerative capacity can address these limitations, and TEHVs could become a promising therapeutic alternative for patients with valvular disease. In this Review, we present a comprehensive overview of current clinically adopted heart valve replacement options, with a focus on transcatheter prostheses. We discuss the various concepts of heart valve tissue engineering underlying the design of next-generation TEHVs, focusing on off-the-shelf technologies. We also summarize the latest preclinical and clinical evidence for the use of these TEHVs and describe the current scientific, regulatory and clinical challenges associated with the safe and broad clinical translation of this technology.
Surgical heart valve replacement is the gold-standard treatment for aortic valve disease, but transcatheter valve implantation has revolutionized the field by providing a novel treatment option for patients of all risk profiles.
Despite rapid advances in the field of heart valve therapy, an unmet clinical need remains for valve replacements with regenerative, remodelling and growth potential.
In situ tissue engineering technologies can be used to produce a heart valve replacement that is readily available, manufactured using decellularized extracellular matrix or bioresorbable polymers, and transforms into a native-equivalent valve after implantation.
Computational modelling is a powerful tool that can be used to improve and accelerate our understanding of tissue-engineered heart valve growth and remodelling and should be used in concert with in vitro and in vivo tissue engineering technologies.
To ensure the good clinical safety, feasibility and efficacy of the tissue-engineered heart valve, researchers and clinicians should work according to Good Manufacturing Practices and Good Laboratory Practices as well as to International Organization for Standardization requirements.
The field of heart valve tissue engineering still faces several challenges, such as issues related to immunocompatibility, haemocompatibility, remodelling and growth capacity, which need to be further investigated before broad clinical adoption is possible.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Baumgartner, H. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 38, 2739–2786 (2017).
Schoen, F. J. & Gotlieb, A. I. Heart valve health, disease, replacement, and repair: a 25-year cardiovascular pathology perspective. Cardiovasc. Pathol. 25, 341–352 (2016).
Schoen, F. J. Morphology, clinicopathologic correlations, and mechanisms in heart valve health and disease. Cardiovasc. Eng. Technol. 9, 126–140 (2018).
Patterson, J. T. et al. Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again. Regen. Med. 7, 409–419 (2012).
Alsoufi, B., Cheung, D. Y., Duan, B. & Butcher, J. T. Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions. Expert Opin. Biol. Ther. 15, 1155–1172 (2015).
Iung, B. & Vahanian, A. Epidemiology of valvular heart disease in the adult. Nat. Rev. Cardiol. 8, 162–172 (2011).
Salik, I., Lee, L. & Widrich, J. Mitral Valve Repair (StatPearls Publishing, 2019).
Guo, M. H. & Boodhwani, M. Aortic valve repair: from concept to future targets. Semin. Thorac. Cardiovasc. Surg. https://doi.org/10.1053/j.semtcvs.2019.05.034 (2019).
Shah, M. & Jorde, U. P. Percutaneous mitral valve interventions (repair): current indications and future perspectives. Front. Cardiovasc. Med. 6, 88 (2019).
Bisleri, G. Aortic valve repair. Curr. Opin. Cardiol. 31, 581–584 (2016).
Said, S. M., Mainwaring, R. D., Ma, M., Tacy, T. A. & Hanley, F. L. Pulmonary valve repair for patients with acquired pulmonary valve insufficiency. Ann. Thorac. Surg. 101, 2294–2301 (2016).
Tabata, N., Sugiura, A., Tsujita, K., Nickenig, G. & Sinning, J.-M. M. in Cardiovascular Intervention and Therapeutics (Springer, 2019).
Yacoub, M. H. & Takkenberg, J. J. M. Will heart valve tissue engineering change the world? Nat. Clin. Pract. Cardiovasc. Med. 2, 60–61 (2005).
Sarkar, M. & Prabhu, V. Basics of cardiopulmonary bypass. Indian J. Anaesth. 61, 760–767 (2017).
Bonhoeffer, P. et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 356, 1403–1405 (2000).
Cribier, A. et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106, 3006–3008 (2002).
Walther, T. et al. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 116, I240–I245 (2007).
Rodés-Cabau, J. et al. Long-term outcomes after transcatheter aortic valve implantation. J. Am. Coll. Cardiol. 60, 1864–1875 (2012).
Leon, M. B. et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N. Engl. J. Med. 374, 1609–1620 (2016).
Reardon, M. J. et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N. Engl. J. Med. 376, 1321–1331 (2017).
Mack, M. J. et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1814052 (2019).
Popma, J. J. et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1816885 (2019).
Hufnagel, C. A. Surgical correction of aortic insufficiency. Mod. Concepts Cardiovasc. Dis. 24, 287–289 (1955).
Russo, M. et al. The evolution of surgical valves. Cardiovasc. Med. 20, 285–292 (2017).
Head, S. J., Çelik, M. & Kappetein, A. P. Mechanical versus bioprosthetic aortic valve replacement. Eur. Heart J. 38, 2183–2191 (2017).
Soliman Hamad, M. A., van Eekelen, E., van Agt, T. & van Straten, A. H. M. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur. J. Cardiothorac. Surg. 35, 265–269 (2009).
Nishimura, R. A. & Warnes, C. A. Anticoagulation during pregnancy in women with prosthetic valves: evidence, guidelines and unanswered questions: Table 1. Heart 101, 430–435 (2015).
Murray, G., Roschlau, W. & Lougheed, W. Homologous aortic-valve-segment transplants as surgical treatment for aortic and mitral insufficiency. Angiology 7, 466–471 (1956).
Ross, D. N. Homograft replacement of the aortic valve. Lancet 280, 487 (1962).
Lisy, M. et al. Allograft heart valves: current aspects and future applications. Biopreserv. Biobank 15, 148–157 (2017).
Meijer, F. M. M. et al. Excellent durability of homografts in pulmonary position analysed in a predefined adult group with tetralogy of Fallot. Interact. Cardiovasc. Thorac. Surg. 28, 279–283 (2019).
Bonetti, A., Marchini, M. & Ortolani, F. Ectopic mineralization in heart valves: new insights from in vivo and in vitro procalcific models and promising perspectives on noncalcifiable bioengineered valves. J. Thorac. Dis. 11, 2126–2143 (2019).
Delmo Walter, E. M., de By, T. M. M. H., Meyer, R. & Hetzer, R. The future of heart valve banking and of homografts: perspective from the Deutsches Herzzentrum Berlin. HSR Proc. Intensive Care Cardiovasc. Anesth. 4, 97–108 (2012).
Blum, K. M., Drews, J. D. & Breuer, C. K. Tissue-engineered heart valves: a call for mechanistic studies. Tissue Eng. Part B Rev. 24, 240–253 (2018).
Etnel, J. R. G. et al. Outcome after aortic valve replacement in children: a systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. 151, 143–152.e1-3 (2016).
Schenke-Layland, K. et al. Impact of cryopreservation on extracellular matrix structures of heart valve leaflets. Ann. Thorac. Surg. 81, 918–926 (2006).
Pfitzner, R. et al. Influence of cryopreservation on structural, chemical, and immunoenzymatic properties of aortic valve allografts. Transplant. Proc. 50, 2195–2198 (2018).
Nappi, F. et al. Long-term outcome of cryopreserved allograft for aortic valve replacement. J. Thorac. Cardiovasc. Surg. 156, 1357–1365.e6 (2018).
Fukushima, S. et al. Long-term clinical outcomes after aortic valve replacement using cryopreserved aortic allograft. J. Thorac. Cardiovasc. Surg. 148, 65–72.e2 (2014).
Flameng, W., Daenen, W., Jashari, R., Herijgers, P. & Meuris, B. Durability of homografts used to treat complex aortic valve endocarditis. Ann. Thorac. Surg. 99, 1234–1238 (2015).
Manji, R. A., Lee, W. & Cooper, D. K. C. Xenograft bioprosthetic heart valves: past, present and future. Int. J. Surg. 23, 280–284 (2015).
Loger, K. et al. Transcatheter mitral valve implantation: supra-annular and subvalvular fixation techniques. Eur. J. Cardiothorac. Surg. 54, 1013–1021 (2018).
Tavakoli, R. et al. Biological aortic valve replacement: advantages and optimal indications of stentless compared to stented valve substitutes. A review. Gen. Thorac. Cardiovasc. Surg. 66, 247–256 (2018).
Bilkhu, R., Borger, M. A., Briffa, N. P. & Jahangiri, M. Sutureless aortic valve prostheses. Heart 105, s16–s20 (2019).
Thiene, G. & Valente, M. Anticalcification strategies to increase bioprosthetic valve durability. J. Heart Valve Dis. 20, 37–44 (2011).
Wiegerinck, E. M. A., Van Kesteren, F., Van Mourik, M. S., Vis, M. M. & Baan, J. Jr. An up-to-date overview of the most recent transcatheter implantable aortic valve prostheses. Expert Rev. Med. Devices 13, 31–45 (2016).
Arsalan, M. & Walther, T. Durability of prostheses for transcatheter aortic valve implantation. Nat. Rev. Cardiol. 13, 360–367 (2016).
Niclauss, L., von Segesser, L. K. & Ferrari, E. Aortic biological valve prosthesis in patients younger than 65 years of age: transition to a flexible age limit? Interact. Cardiovasc. Thorac. Surg. 16, 501–507 (2013).
David, T. E. Reoperations after the Ross procedure. Circulation 122, 1139–1140 (2010).
Riess, F.-C. et al. Hemodynamic performance of the medtronic mosaic porcine bioprosthesis up to ten years. Ann. Thorac. Surg. 83, 1310–1318 (2007).
Human, P. & Zilla, P. The neglected villain of bioprosthetic degeneration: inflammatory and immune processes. J. Long. Term. Eff. Med. Implant. 27, 159–180 (2017).
Fishbein, G. A. & Fishbein, M. C. Pathology of the aortic valve: aortic valve stenosis/aortic regurgitation. Curr. Cardiol. Rep. 21, 81 (2019).
Rabkin-Aikawa, E., Mayer, J. E. & Schoen, F. J. Heart valve regeneration. Adv. Biochem. Eng. Biotechnol. 94, 141–179 (2005).
Ross, D. N. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 2, 956–958 (1967).
Bowdish, M. E., Ram Kumar, S. & Starnes, V. A. The Ross procedure: an excellent option in the right hands. Ann. Transl Med. 4, 1–3 (2016).
Mazine, A. et al. Long-term outcomes of the Ross procedure versus mechanical aortic valve replacement: propensity-matched cohort study. Circulation 134, 576–585 (2016).
Tam, D. Y., Wijeysundera, H. C., Ouzounian, M. & Fremes, S. E. The Ross procedure versus mechanical aortic valve replacement in young patients: a decision analysis. Eur. J. Cardiothorac. Surg. 55, 1180–1186 (2019).
Thom, H. et al. Clinical and cost-effectiveness of the Ross procedure versus conventional aortic valve replacement in young adults. Open Heart 6, e001047 (2019).
Roe, B. B. Late follow-up studies on flexible leaflet prosthetic valves. J. Thorac. Cardiovasc. Surg. 58, 59–61 (1969).
Ando, M. & Takahashi, Y. Ten-year experience with handmade trileaflet polytetrafluoroethylene valved conduit used for pulmonary reconstruction. J. Thorac. Cardiovasc. Surg. 137, 124–131 (2009).
Mackay, T. G., Wheatley, D. J., Bernacca, G. M., Fisher, A. C. & Hindle, C. S. New polyurethane heart valve prosthesis: design, manufacture and evaluation. Biomaterials 17, 1857–1863 (1996).
Bezuidenhout, D., Williams, D. F. & Zilla, P. Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices. Biomaterials 36, 6–25 (2015).
Hilbert, S. L., Ferrans, V. J., Tomita, Y., Eidbo, E. E. & Jones, M. Evaluation of explanted polyurethane trileaflet cardiac valve prostheses. J. Thorac. Cardiovasc. Surg. 94, 419–429 (1987).
Jansen, J. & Reul, H. A synthetic three-leaflet valve. J. Med. Eng. Technol. 16, 27–33 (1992).
Daebritz, S. H. et al. New flexible polymeric heart valve prostheses for the mitral and aortic positions. Heart Surg. Forum 7, E525–E532 (2004).
Nistal, F. et al. In vivo experimental assessment of polytetrafluoroethylene trileaflet heart valve prosthesis. J. Thorac. Cardiovasc. Surg. 99, 1074–1081 (1990).
Hirai, S. et al. Assessment of a new silicone tri-leaflet valve seamlessly assembled with blood chamber for a low-cost ventricular assist device. Hiroshima J. Med. Sci. 47, 47–55 (1998).
Dandeniyage, L. S. et al. Morphology and surface properties of high strength siloxane poly(urethane-urea)s developed for heart valve application. J. Biomed. Mater. Res. Part B Appl. Biomater. 107, 112–121 (2019).
Dandeniyage, L. S. et al. Development of high strength siloxane poly(urethane-urea) elastomers based on linked macrodiols for heart valve application. J. Biomed. Mater. Res. Part B Appl. Biomater. 106, 1712–1720 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03851068 (2019).
Yakubov, S. Foldax® Tria: first in human implant of a totally synthetic polymeric aortic valve. Cardiovascular Research Technologies (CRT) https://www.crtonline.org/crt-premium-detail/foldax-tria-first-in-human-implant-of-totally-synt (2020).
Scherman, J. et al. Transcatheter valve with a hollow balloon for aortic valve insufficiency. Multimed. Man. Cardiothorac. Surg. https://doi.org/10.1510/mmcts.2018.012 (2018).
Henaine, R., Roubertie, F., Vergnat, M. & Ninet, J. Valve replacement in children: a challenge for a whole life. Arch. Cardiovasc. Dis. 105, 517–528 (2012).
Huygens, S. A. et al. Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts:a systematic review and meta-analysis. Eur. J. Cardiothorac. Surg. 50, 605–616 (2016).
Huygens, S. A., Goossens, L. M. A., Van Erkelens, J. A., Takkenberg, J. J. M. & Rutten-Van Mölken, M. P. M. H. How much does a heart valve implantation cost and what are the health care costs afterwards? Open Heart 5, e000672 (2018).
Harken, D. E. Heart valves: ten commandments and still counting. Ann. Thorac. Surg. 48 (Suppl. 3), 18–19 (1989).
Langer, R. & Vacanti, J. P. Tissue engineering. Science 260, 920–926 (1993).
Mendelson, K. & Schoen, F. J. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann. Biomed. Eng. 34, 1799–1819 (2006).
Cebotari, S. et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114 (Suppl. 1), I132–138 (2006).
Dohmen, P. M. et al. Mid-Term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann. Thorac. Surg. 84, 729–736 (2007).
Dohmen, P. et al. An experimental study of decellularized xenografts implanted into the aortic position with 4 months of follow up. J. Clin. Exp. Cardiol. https://doi.org/10.4172/2155-9880.S4-004 (2012).
Erdbrügger, W. et al. Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng. 12, 2059–2068 (2006).
Hoerstrup, S. P. et al. A new approach to completely autologous cardiovascular tissue in humans. ASAIO J. 48, 234–238 (2002).
Del Gaudio, C., Grigioni, M., Bianco, A. & De Angelis, G. Electrospun bioresorbable heart valve scaffold for tissue engineering. Int. J. Artif. Organs 31, 68–75 (2008).
Sodian, R. et al. Tissue engineering of heart valves: in vitro experiences. Ann. Thorac. Surg. 70, 140–144 (2000).
Hoerstrup, S. P. et al. Functional living trileaflet heart valves grown in vitro. Circulation 102 (Suppl. 3), III44–III49 (2000).
Gottlieb, D. et al. In vivo monitoring of function of autologous engineered pulmonary valve. J. Thorac. Cardiovasc. Surg. 139, 723–731 (2010).
Schmidt, D. et al. Minimally-Invasive implantation of living tissue engineered heart valves. J. Am. Coll. Cardiol. 56, 510–520 (2010).
Weber, B. et al. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: First experiences with a one-step intervention in primates. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehr059 (2011).
Sutherland, F. W. H. et al. From stem cells to viable autologous semilunar heart valve. Circulation 111, 2783–2791 (2005).
Shinoka, T. et al. Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 94 (Suppl. 9), II164–II168 (1996).
Robinson, P. S., Johnson, S. L., Evans, M. C., Barocas, V. H. & Tranquillo, R. T. Functional tissue-engineered valves from cell-remodeled fibrin with commissural alignment of cell-produced collagen. Tissue Eng. Part A 14, 83–95 (2008).
Flanagan, T. C. et al. In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng. Part A 15, 2965–2976 (2009).
Dijkman, P. E. et al. Trans-apical versus surgical implantation of autologous ovine tissue-engineered heart valves. J. Heart Valve Dis. 21, 670–678 (2012).
Beachy, S. H., Wizemann, T. C. & Hackmann, M. (eds) Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products (National Academies Press, 2019).
Dijkman, P. E., Driessen-Mol, A., Frese, L., Hoerstrup, S. P. & Baaijens, F. P. T. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials 33, 4545–4554 (2012).
Wissing, T. B., Bonito, V., Bouten, C. V. C. & Smits, A. I. P. M. Biomaterial-driven in situ cardiovascular tissue engineering — a multi-disciplinary perspective. NPJ Regen. Med. 2, 18 (2017).
Kluin, J. et al. In situ heart valve tissue engineering using a bioresorbable elastomeric implant – from material design to 12 months follow-up in sheep. Biomaterials 125, 101–117 (2017).
Lichtenberg, A. et al. Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation https://doi.org/10.1161/CIRCULATIONAHA.105.001206 (2006).
Biermann, A. C. et al. Improved long-term durability of allogeneic heart valves in the orthotopic sheep model. Eur. J. Cardiothorac. Surg. 55, 484–493 (2019).
Tudorache, I. et al. Decellularized aortic homografts for aortic valve and aorta ascendens replacement. Eur. J. Cardiothorac. Surg. 50, 89–97 (2016).
Sarikouch, S. et al. Decellularized fresh homografts for pulmonary valve replacement: A decade of clinical experience. Eur. J. Cardiothorac. Surg. 50, 281–290 (2016).
Cebotari, S. et al. Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation 124, 115–124 (2011).
Boethig, D. et al. A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data. Eur. J. Cardiothorac. Surg. 56, 503–509 (2019).
Bobylev, D. et al. Double semilunar valve replacement in complex congenital heart disease using decellularized homografts. Interact. Cardiovasc. Thorac. Surg. 28, 151–157 (2019).
Da Costa, F. D. A. et al. The early and midterm function of decellularized aortic valve allografts. Ann. Thorac. Surg. 90, 1854–1860 (2010).
Helder, M. R. K. K. et al. Late durability of decellularized allografts for aortic valve replacement: A word of caution. J. Thorac. Cardiovasc. Surg. 152, 1197–1199 (2016).
Brown, J. W., Ruzmetov, M., Eltayeb, O., Rodefeld, M. D. & Turrentine, M. W. Performance of synergraft decellularized pulmonary homograft in patients undergoing a Ross procedure. Ann. Thorac. Surg. 91, 416–423 (2011).
Burch, P. T. et al. Clinical performance of decellularized cryopreserved valved allografts compared with standard allografts in the right ventricular outflow tract. Ann. Thorac. Surg. 90, 1301–1306 (2010).
Konertz, W. et al. Right ventricular outflow tract reconstruction with decellularized porcine xenografts in patients with congenital heart disease. J. Heart Valve Dis. 20, 341–347 (2011).
Sayk, F., Bos, I., Schubert, U., Wedel, T. & Sievers, H.-H. Histopathologic findings in a novel decellularized pulmonary homograft: an autopsy study. Ann. Thorac. Surg. 79, 1755–1758 (2005).
Helder, M. R. K. et al. Low-dose gamma irradiation of decellularized heart valves results in tissue injury in vitro and in Vivo. Ann. Thorac. Surg. 101, 667–674 (2016).
Ruiz, C. E. et al. Transcatheter placement of a low-profile biodegradable pulmonary valve made of small intestinal submucosa: a long-term study in a swine model. J. Thorac. Cardiovasc. Surg. 130, 477–484 (2005).
Fallon, A. M., Goodchild, T. T., Cox, J. L. & Matheny, R. G. In vivo remodeling potential of a novel bioprosthetic tricuspid valve in an ovine model. J. Thorac. Cardiovasc. Surg. 148, 333–340.e1 (2014).
Zafar, F. et al. Physiological growth, remodeling potential, and preserved function of a novel bioprosthetic tricuspid valve: tubular bioprosthesis made of small intestinal submucosa-derived extracellular matrix. J. Am. Coll. Cardiol. 66, 877–888 (2015).
van Rijswijk, J. W. et al. Failure of decellularized porcine small intestinal submucosa as a heart valved conduit. J. Thorac. Cardiovasc. Surg. https://doi.org/10.1016/j.jtcvs.2019.09.164 (2020).
Woo, J. S., Fishbein, M. C. & Reemtsen, B. Histologic examination of decellularized porcine intestinal submucosa extracellular matrix (CorMatrix) in pediatric congenital heart surgery. Cardiovasc. Pathol. 25, 12–17 (2016).
Filippo, N., Paola, A. & Laura, I. Biocompatibility evaluation criteria for novel xenograft materials: distribution and quantification of remnant nucleic acid and alpha-gal epitope. J. Stem Cell Res. Ther. https://doi.org/10.4172/2157-7633.S6-009 (2013).
Mosala Nezhad, Z. et al. Small intestinal submucosa extracellular matrix (CorMatrix®) in cardiovascular surgery: a systematic review. Interact. Cardiovascular Thorac. Surg. 22, 839–850 (2016).
Padalino, M. A. et al. Porcine intestinal submucosa (CorMatrix) for semilunar valve repair in children: a word of caution after midterm results. Semin. Thorac. Cardiovasc. Surg. 28, 436–445 (2016).
Hofmann, M. et al. Congenital aortic valve repair using CorMatrix®: a histologic evaluation. Xenotransplantation https://doi.org/10.1111/xen.12341 (2017).
Mosala Nezhad, Z., Poncelet, A., Fervaille, C., De Kerchove, L. & Gianello, P. Experimental aortic valve cusp extension with cormatrix in a porcine model. Thorac. Cardiovasc. Surg. 65, 206–210 (2017).
Mosala Nezhad, Z. et al. CorMatrix valved conduit in a porcine model: long-term remodelling and biomechanical characterization. Interact. Cardiovasc. Thorac. Surg. 24, 90–98 (2017).
Mosala Nezhad, Z., Baldin, P., Poncelet, A. & El Khoury, G. Calcific degeneration of CorMatrix 4 years after bicuspidization of unicuspid aortic valve. Ann. Thorac. Surg. 104, e431–e433 (2017).
Zaidi, A. H. et al. Preliminary experience with porcine intestinal submucosa (CorMatrix) for valve reconstruction in congenital heart disease: Histologic evaluation of explanted valves. J. Thorac. Cardiovasc. Surg. 148, 2216–2225.e1 (2014).
Gilbert, C. L., Gnanapragasam, J., Benhaggen, R. & Novick, W. M. Novel use of extracellular matrix graft for creation of pulmonary valved conduit. World J. Pediatr. Congenit. Heart Surg. 2, 495–501 (2011).
Gerdisch, M., Stelly, T., Slaughter, M. & Rodriguez, V. Early results from the FDA extracellular matrix (ECM) cylinder valve clinical feasibility trial. Structural Heart 4, 102 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02397668 (2015).
Iwai, S., Torikai, K., Coppin, C. M. & Sawa, Y. Minimally immunogenic decellularized porcine valve provides in situ recellularization as a stentless bioprosthetic valve. J. Artif. Organs 10, 29–35 (2007).
Dohmen, P. M. et al. Results of a decellularized porcine heart valve implanted into the juvenile sheep model. Heart Surg. Forum 8, 72–76 (2005).
Leyh, R. G. et al. Acellularized porcine heart valve scaffolds for heart valve tissue engineering and the risk of cross-species transmission of porcine endogenous retrovirus. J. Thorac. Cardiovasc. Surg. 126, 1000–1004 (2003).
Konertz, W. et al. Hemodynamic characteristics of the Matrix P decellularized xenograft for pulmonary valve replacement during the Ross operation. J. Heart Valve Dis. 14, 78–81 (2005).
Christ, T. et al. Long-term results after the Ross procedure with the decellularized autotissue matrix P® bioprosthesis used for pulmonary valve replacement. Eur. J. Cardiothorac. Surg. 55, 885–892 (2019).
Perri, G. et al. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease. Eur. J. Cardiothorac. Surg. 41, 1320–1325 (2012).
Backhoff, D., Steinmetz, M., Sigler, M. & Schneider, H. Formation of multiple conduit aneurysms following Matrix P® conduit implantation in a boy with tetralogy of Fallot and pulmonary atresia. Eur. J. Cardiothorac. Surg. 46, 500–502 (2014).
Breitenbach, I. et al. Early failure of decellularized xenogenous pulmonary valve conduit (Matrix-P-Plus) for reconstruction of the right ventricular outflow tract in the Ross procedure. Thorac. Cardiovasc. Surg. 62, OP123 (2014).
Simon, P. et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur. J. Cardiothorac. Surg. 23, 1002–1006 (2003).
Crapo, P. M., Gilbert, T. W. & Badylak, S. F. An overview of tissue and whole organ decellularization processes. Biomaterials 32, 3233–3243 (2011).
Goecke, T. et al. In vivo performance of freeze-dried decellularized pulmonary heart valve allo- and xenografts orthotopically implanted into juvenile sheep. Acta Biomater. 68, 41–52 (2018).
Hennessy, R. S. et al. Recellularization of a novel off-the-shelf valve following xenogenic implantation into the right ventricular outflow tract. PLoS ONE 12, e0181614 (2017).
Weber, B. et al. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials 34, 7269–7280 (2013).
Hopkins, R. A. et al. Bioengineered human and allogeneic pulmonary valve conduits chronically implanted orthotopically in baboons: Hemodynamic performance and immunologic consequences. J. Thorac. Cardiovasc. Surg. 145, 1098–1107.e3 (2013).
Syedain, Z. H., Meier, L. A., Lahti, M. T., Johnson, S. L. & Tranquillo, R. T. Implantation of completely biological engineered grafts following decellularization into the sheep femoral artery. Tissue Eng. Part A 20, 1726–1734 (2014).
Emmert, M. Y. et al. Computational modeling guides tissue-engineered heart valve design for long-term in vivo performance in a translational sheep model. Sci. Transl Med. 10, an4587 (2018).
Motta, S. E. et al. Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements. NPJ Regen. Med. 4, 14 (2019).
Motta, S. E. et al. Development of an off-the-shelf tissue-engineered sinus valve for transcatheter pulmonary valve replacement: a proof-of-concept study. J. Cardiovasc. Transl Res. 11, 182–191 (2018).
Lintas, V. et al. Development of a novel human cell-derived tissue-engineered heart valve for transcatheter aortic valve replacement: an in vitro and in vivo feasibility study. J. Cardiovasc. Transl Res. 11, 470–482 (2018).
Syedain, Z. H. et al. A completely biological ‘off-the-shelf’ arteriovenous graft that recellularizes in baboons. Sci. Transl Med. 9, eaan4209 (2017).
Reimer, J. M., Syedain, Z. H., Haynie, B. H. T. & Tranquillo, R. T. Pediatric tubular pulmonary heart valve from decellularized engineered tissue tubes. Biomaterials 62, 88–94 (2015).
Syedain, Z. et al. 6-month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep. Biomaterials 73, 175–184 (2015).
Driessen-Mol, A. et al. Transcatheter implantation of homologous ‘off-the-shelf’ tissue-engineered heart valves with self-repair capacity: Long-term functionality and rapid in vivo remodeling in sheep. J. Am. Coll. Cardiol. 63, 1320–1329 (2014).
Reimer, J. et al. Implantation of a tissue-engineered tubular heart valve in growing lambs. Ann. Biomed. Eng. 45, 439–451 (2017).
Kirkton, R. D. et al. Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation. Sci. Transl Med. 11, eaau6934 (2019).
Lawson, J. H. et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 387, 2026–2034 (2016).
Jana, S., Tefft, B. J., Spoon, D. B. & Simari, R. D. Scaffolds for tissue engineering of cardiac valves. Acta Biomater. 10, 2877–2893 (2014).
Soliman, O. I. et al. Midterm performance of a novel restorative pulmonary valved conduit: Preclinical results. EuroIntervention 13, e1418–e1427 (2017).
Capulli, A. K. et al. JetValve: Rapid manufacturing of biohybrid scaffolds for biomimetic heart valve replacement. Biomaterials 133, 229–241 (2017).
Miyazaki, Y. et al. Acute performance of a novel restorative transcatheter aortic valve: preclinical results. EuroIntervention 13, e1410–e1417 (2017).
Bennink, G. et al. A novel restorative pulmonary valved conduit in a chronic sheep model: mid-term hemodynamic function and histologic assessment. J. Thorac. Cardiovasc. Surg. 155, 2591–2601.e3 (2018).
Coyan, G. N. et al. In vivo functional assessment of a novel degradable metal and elastomeric scaffold-based tissue engineered heart valve. J. Thorac. Cardiovasc. Surg. 157, 1809–1816 (2019).
Emmert, M. Y. et al. Transapical aortic implantation of autologous marrow stromal cell-based tissue-engineered heart valves: first experiences in the systemic circulation. JACC Cardiovasc. Interv. 4, 822–823 (2011).
Emmert, M. Y. et al. Stem cell-based transcatheter aortic valve implantation: first experiences in a pre-clinical model. JACC Cardiovasc. Interv. 5, 874–883 (2012).
Emmert, M. Y. et al. Transcatheter aortic valve implantation using anatomically oriented, marrow stromal cell-based, stented, tissue-engineered heart valves: technical considerations and implications for translational cell-based heart valve concepts. Eur. J. Cardiothorac. Surg. 45, 61–68 (2014).
Fioretta, E. S. et al. Differential leaflet remodeling of bone marrow cell pre-seeded versus nonseeded bioresorbable transcatheter pulmonary valve replacements. JACC Basic Transl Sci. 5, 15–31 (2019).
Fioretta, E. et al. A multidisciplinary study to develop a transcatheter aortic valve implantation system for in situ heart valve tissue engineering. Structural Heart 4, 57 (2020).
Bockeria, L. et al. Total cavopulmonary connection with a new bioabsorbable vascular graft: first clinical experience. J. Thorac. Cardiovasc. Surg. 153, 1542–1550 (2017).
Bennink, G. et al. A in International Conference of Tissue Engineered Heart Valves 37–38 (ICTEHV, 2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02700100 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03022708 (2017).
Miller, D. V., Edwards, W. D. & Zehr, K. J. Endothelial and smooth muscle cell populations in a decellularized cryopreserved aortic homograft (SynerGraft) 2 years after implantation. J. Thorac. Cardiovasc. Surg. 132, 175–176 (2006).
Choi, S.-Y. et al. Elimination of alpha-gal xenoreactive epitope: alpha-galactosidase treatment of porcine heart valves. J. Heart Valve Dis. 21, 387–397 (2012).
Abdolghafoorian, H. et al. Effect of heart valve decellularization on xenograft rejection. Exp. Clin. Transplant. 15, 329–336 (2017).
Park, S., Kim, W.-H., Choi, S.-Y. & Kim, Y.-J. Removal of alpha-gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A. J. Korean Med. Sci. 24, 1126 (2009).
Goecke, T., Hilfiker, A., Haverich, A. & Cebotari, S. Investigation of inflammatory response of decellularized porcine aortic tissue in mice: can we rely on this experimental setting? Eur. J. Cardiothorac. Surg. 47, e90–e91 (2015).
Smits, A. I. P. M., Ballotta, V., Driessen-Mol, A., Bouten, C. V. C. & Baaijens, F. P. T. Shear flow affects selective monocyte recruitment into MCP-1-loaded scaffolds. J. Cell. Mol. Med. 18, 2176–2188 (2014).
Bonito, V., de Kort, B. J., Bouten, C. V. C. & Smits, A. I. P. M. Cyclic strain affects macrophage cytokine secretion and extracellular matrix turnover in electrospun scaffolds. Tissue Eng. Part A 25, 1310–1325 (2019).
Sanders, B., Driessen-Mol, A., Bouten, C. V. C. & Baaijens, F. P. T. The Effects of scaffold remnants in decellularized tissue-engineered cardiovascular constructs on the recruitment of blood cells. Tissue Eng. Part A 23, 1142–1151 (2017).
Li, G. et al. The shift of macrophages toward M1 phenotype promotes aortic valvular calcification. J. Thorac. Cardiovasc. Surg. 153, 1318–1327.e1 (2017).
Seyfert, U. T., Biehl, V. & Schenk, J. In vitro hemocompatibility testing of biomaterials according to the ISO 10993-4. Biomol. Eng. 19, 91–96 (2002).
Weber, M. et al. Blood-contacting biomaterials: in vitro evaluation of the hemocompatibility. Front. Bioeng. Biotechnol. 6, 99 (2018).
Xu, X. X., Gao, X. H., Pan, R., Lu, D. & Dai, Y. A simple adhesion assay for studying interactions between platelets and endothelial cells in vitro. Cytotechnology 62, 17–22 (2010).
Ariëns, R. A. S. Novel mechanisms that regulate clot structure/function. Thromb. Res. 141 (Suppl. 2), 25–27 (2016).
Herring, M. B. Endothelial cell seeding. J. Vasc. Surg. 13, 731–732 (1991).
Rotmans, J. I. et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 112, 12–18 (2005).
Melchiorri, A. J. et al. Contrasting biofunctionalization strategies for the enhanced endothelialization of biodegradable vascular grafts. Biomacromolecules 16, 437–446 (2015).
Jordan, J. E. et al. Bioengineered self-seeding heart valves. J. Thorac. Cardiovasc. Surg. 143, 201–208 (2012).
Rodenberg, E. J. & Pavalko, F. M. Peptides derived from fibronectin type III connecting segments promote endothelial cell adhesion but not platelet adhesion: Implications in tissue-engineered vascular grafts. Tissue Eng. 13, 2653–2666 (2007).
Caiado, F. et al. The role of fibrin E on the modulation of endothelial progenitors adhesion, differentiation and angiogenic growth factor production and the promotion of wound healing. Biomaterials 32, 7096–7105 (2011).
Aubin, H. et al. Customized interface biofunctionalization of decellularized extracellular matrix: towards enhanced endothelialization. Tissue Eng. Part C. Methods 22, 496–508 (2016).
Smith, R. J., Koobatian, M. T., Shahini, A., Swartz, D. D. & Andreadis, S. T. Capture of endothelial cells under flow using immobilized vascular endothelial growth factor. Biomaterials 51, 303–312 (2015).
Namiri, M. et al. Improving the biological function of decellularized heart valves through integration of protein tethering and three-dimensional cell seeding in a bioreactor. J. Tissue Eng. Regen. Med. 12, e1865–e1879 (2018).
Pawlowski, K. J., Rittgers, S. E., Schmidt, S. P. & Bowlin, G. L. Endothelial cell seeding of polymeric vascular grafts. Front. Biosci. 9, 1412 (2004).
Dohmen, P. M. et al. A tissue engineered heart valve implanted in a juvenile sheep model. Med. Sci. Monit. 9, BR97–BR104 (2003).
Dohmen, P. M., Lembcke, A., Holinski, S., Pruss, A. & Konertz, W. Ten years of clinical results with a tissue-engineered pulmonary valve. Ann. Thorac. Surg. 92, 1308–1314 (2011).
Herring, M. et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J. Vasc. Surg. 20, 650–655 (1994).
Koenig, F. et al. Is transcatheter aortic valve implantation of living tissue-engineered valves feasible? An In vitro evaluation utilizing a decellularized and reseeded biohybrid valve. Artif. Organs 40, 727–737 (2016).
Akhyari, P. et al. A novel culture device for the evaluation of three-dimensional extracellular matrix materials. J. Tissue Eng. Regen. Med. 8, 673–681 (2014).
Wang, K. et al. Three-layered PCL grafts promoted vascular regeneration in a rabbit carotid artery model. Macromol. Biosci. 16, 608–918 (2016).
Bachmann, B. J. et al. Honeycomb-structured metasurfaces for the adaptive nesting of endothelial cells under hemodynamic loads. Biomater. Sci. 6, 2726–2737 (2018).
Soares, A. L. F., Oomens, C. W. J. & Baaijens, F. P. T. A computational model to describe the collagen orientation in statically cultured engineered tissues. Comput. Methods Biomech. Biomed. Engin. 17, 251–262 (2014).
Borazjani, I. A review of fluid-structure interaction simulations of prosthetic heart valves. J. Long. Term. Eff. Med. Implant. 25, 75–93 (2015).
Sotiropoulos, F. & Borazjani, I. A review of state-of-the-art numerical methods for simulating flow through mechanical heart valves. Med. Biol. Eng. Comput. 47, 245–256 (2009).
Sanders, B. et al. Improved geometry of decellularized tissue engineered heart valves to prevent leaflet retraction. Ann. Biomed. Eng. 44, 1061–1071 (2016).
Hoerstrup, S. P. et al. Functional growth in tissue-engineered living, vascular grafts: follow-up at 100 weeks in a large animal model. Circulation 114 (Suppl. 1), I159–166 (2006).
Lu, L. et al. Tissue engineered constructs: perspectives on clinical translation. Ann. Biomed. Eng. 43, 796–804 (2015).
Emmert, M. Y., Fioretta, E. S. & Hoerstrup, S. P. Translational challenges in cardiovascular tissue engineering. J. Cardiovasc. Transl Res. 10, 139–149 (2017).
Salmikangas, P. et al. Marketing regulatory oversight of advanced therapy medicinal products (ATMPs) in Europe: the EMA/CAT perspective. Adv. Exp. Med. Biol. 871, 103–130 (2015).
Hurtado-Aguilar, L. G. et al. Ultrasound for in vitro, noninvasive real-time monitoring and evaluation of tissue-engineered heart valves. Tissue Eng. Part C Methods 22, 974–981 (2016).
Tipnis, N. P. & Burgess, D. J. Sterilization of implantable polymer-based medical devices: a review. Int. J. Pharm. 544, 455–460 (2018).
Durko, A. P. et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur. Heart J. 39, 2635–2642 (2018).
Santarpino, G., Specchia, L. & Lombardi, L. Aortic valve implantation or replacement: which procedure is more cost-effective? J. Thorac. Cardiovasc. Surg. 156, 1851 (2018).
Huygens, S. A., Takkenberg, J. J. M. & Rutten-van Mölken, M. P. M. H. Systematic review of model-based economic evaluations of heart valve implantations. Eur. J. Health Econ. 19, 241–255 (2018).
Tam, D. Y. et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. J. Thorac. Cardiovasc. Surg. 155, 1978–1988.e1 (2018).
Huygens, S. A. et al. What is the potential cost-effectiveness of tissue-engineered heart valves? Structural Heart 3, 60–60 (2019).
Huygens, S. A. et al. Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients. Eur. J. Health Econ. https://doi.org/10.1007/s10198-020-01159-y (2020).
Loerakker, S., Ristori, T. & Baaijens, F. P. T. T. A computational analysis of cell-mediated compaction and collagen remodeling in tissue-engineered heart valves. J. Mech. Behav. Biomed. Mater. 58, 173–187 (2016).
Zakerzadeh, R., Hsu, M. C. & Sacks, M. S. Computational methods for the aortic heart valve and its replacements. Expert Rev. Med. Devices 14, 849–866 (2017).
Xu, F. et al. A framework for designing patient-specific bioprosthetic heart valves using immersogeometric fluid-structure interaction analysis. Int. J. Numer. Method Biomed. Eng. 34, e2938 (2018).
Khosravi, R. et al. Biomechanical diversity despite mechanobiological stability in tissue engineered vascular grafts two years post-implantation. Tissue Eng. Part A 21, 1529–1538 (2015).
Best, C. A. et al. Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling. Acta Biomater. 94, 183–194 (2019).
Miller, K. S., Lee, Y. U., Naito, Y., Breuer, C. K. & Humphrey, J. D. Computational model of the in vivo development of a tissue engineered vein from an implanted polymeric construct. J. Biomech. 47, 2080–2087 (2014).
Szafron, J. M. et al. Immuno-driven and mechano-mediated neotissue formation in tissue engineered vascular grafts. Ann. Biomed. Eng. 46, 1938–1950 (2018).
Loerakker, S., Argento, G., Oomens, C. W. J. & Baaijens, F. P. T. Effects of valve geometry and tissue anisotropy on the radial stretch and coaptation area of tissue-engineered heart valves. J. Biomech. 46, 1792–1800 (2013).
Szafron, J. M., Ramachandra, A. B., Breuer, C. K., Marsden, A. L. & Humphrey, J. D. Optimization of tissue-engineered vascular graft design using computational modeling. Tissue Eng. Part C. Methods 25, 561–570 (2019).
Ristori, T., Obbink-Huizer, C., Oomens, C. W. J., Baaijens, F. P. T. & Loerakker, S. Efficient computational simulation of actin stress fiber remodeling. Comput. Methods Biomech. Biomed. Engin. 19, 1347–1358 (2016).
Latorre, M. & Humphrey, J. D. A mechanobiologically equilibrated constrained mixture model for growth and remodeling of soft tissues. Z. Angew. Math. Mech. 98, 2048–2071 (2018).
Latorre, M. & Humphrey, J. D. Critical roles of time-scales in soft tissue growth and remodeling. APL Bioeng. 2, 026108 (2018).
Boyle, P. M. et al. Computationally guided personalized targeted ablation of persistent atrial fibrillation. Nat. Biomed. Eng. 3, 870–879 (2019).
Alber, M. et al. Integrating machine learning and multiscale modeling-perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences. NPJ Digit. Med. 2, 115 (2019).
Matai, I., Kaur, G., Seyedsalehi, A., McClinton, A. & Laurencin, C. T. Progress in 3D bioprinting technology for tissue/organ regenerative engineering. Biomaterials 226, 119536 (2020).
Dasgupta, Q. & Black, L. D. A FRESH SLATE for 3D bioprinting. Science 365, 446–447 (2019).
Lee, A. et al. 3D bioprinting of collagen to rebuild components of the human heart. Science 365, 482–487 (2019).
Coulter, F. B. et al. Bioinspired heart valve prosthesis made by silicone additive manufacturing. Matter 1, 266–279 (2019).
Diment, L. E., Thompson, M. S. & Bergmann, J. H. M. Clinical efficacy and effectiveness of 3D printing: a systematic review. BMJ Open 7, e016891 (2017).
Rotman, O. M., Bianchi, M., Ghosh, R. P., Kovarovic, B. & Bluestein, D. Principles of TAVR valve design, modelling, and testing. Expert Rev. Med. Devices 15, 771–791 (2018).
Zakko, J. et al. Development of tissue engineered heart valves for percutaneous transcatheter delivery in a fetal ovine model. JACC Basic Transl Sci. 5, 815–828 (2020).
Borhani, S., Hassanajili, S., Ahmadi Tafti, S. H. & Rabbani, S. Cardiovascular stents: overview, evolution, and next generation. Prog. Biomater. 7, 175–205 (2018).
Cabrera, M. S. et al. Computationally designed 3D printed self-expandable polymer stents with biodegradation capacity for minimally invasive heart valve implantation: a proof-of-concept study. 3D Print. Addit. Manuf. 4, 19–29 (2017).
Liu, L. et al. Biodegradability and platelets adhesion assessment of magnesium-based alloys using a microfluidic system. PLoS ONE 12, e0182914 (2017).
Wang, J. et al. Ex vivo blood vessel bioreactor for analysis of the biodegradation of magnesium stent models with and without vessel wall integration. Acta Biomater. 50, 546–555 (2017).
Eibschitz, I., Abinader, E. G., Klein, A. & Sharf, M. Intrauterine diagnosis and control of fetal ventricular arrhythmia during labor. Am. J. Obstet. Gynecol. 122, 597–600 (1975).
McElhinney, D. B., Tworetzky, W. & Lock, J. E. Current status of fetal cardiac intervention. Circulation 121, 1256–1263 (2010).
Maxwell, D., Allan, L. & Tynan, M. J. Balloon dilatation of the aortic valve in the fetus: A report of two cases. Br. Heart J. 65, 256–258 (1991).
McElhinney, D. B. et al. Predictors of technical success and postnatal biventricular outcome after in utero aortic valvuloplasty for aortic stenosis with evolving hypoplastic left heart syndrome. Circulation 120, 1482–1490 (2009).
Flake, A. W. Surgery in the human fetus: the future. J. Physiol. 547, 45–51 (2003).
Weber, B. et al. Fetal trans-apical stent delivery into the pulmonary artery: prospects for prenatal heart-valve implantation. Eur. J. Cardiothorac. Surg. 41, 398–403 (2012).
Colwell, A. S., Longaker, M. T. & Lorenz, H. P. Mammalian fetal organ regeneration. Adv. Biochem. Eng. Biotechnol. 93, 83–100 (2005).
van der Merwe, J. & Casselman, F. Mitral valve replacement — current and future perspectives. Open J. Cardiovasc. Surg. 9, 117906521771902 (2017).
Muller, D. W. M. Transcatheter mitral valve replacement: slow and steady progress. J. Thorac. Dis. 10, S1949–S1952 (2018).
Zehr, K. J., Yagubyan, M., Connolly, H. M., Nelson, S. M. & Schaff, H. V. Aortic root replacement with a novel decellularized cryopreserved aortic homograft: postoperative immunoreactivity and early results. J. Thorac. Cardiovasc. Surg. 130, 1010–1015 (2005).
Hawkins, J. A. et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: Comparison with standard cryopreserved allografts. J. Thorac. Cardiovasc. Surg. 126, 247–253 (2003).
Takagi, K. et al. In vivo recellularization of plain decellularized xenografts with specific cell characterization in the systemic circulation: histological and immunohistochemical study. Artif. Organs 30, 233–241 (2006).
Ota, T. et al. Fibronectin-hepatocyte growth factor enhances reendothelialization in tissue-engineered heart valve. Ann. Thorac. Surg. 80, 1794–1801 (2005).
O’Brien, M. F. et al. The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin. Thorac. Cardiovasc. Surg. 11, 194–200 (1999).
Voges, I. et al. Adverse results of a decellularized tissue-engineered pulmonary valve in humans assessed with magnetic resonance imaging. Eur. J. Cardiothorac. Surg. 44, 272–279 (2013).
Rüffer, A. et al. Early failure of xenogenous de-cellularised pulmonary valve conduits - a word of caution! Eur. J. Cardiothorac. Surg. 38, 78–85 (2010).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03631056 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03183245 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02644941 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03005418 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02887859 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01872208 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03405636 (2018).
Shi, W., Keefe, M. & Matalanis, G. in Aortic Valve Surgery Ch. 5 (IntechOpen, 2011).
E.S.F. was supported by the Swiss National Science Foundation (PZ00P3_180138). M.Y.E. and S.L. have received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme, grant agreement no. 852814 (TAVI4Life) and grant agreement no. 802967 (MechanoSignaling).
F.P.T.B. and S.P.H. are shareholders at LifeMatrix and Xeltis. V.F. declares financial activities with Boston Scientific, Edwards Lifesciences and Medtronic in relation to educational grants (including travel support), fees for lectures and speeches, fees for professional consultation, and research and study funds. M.Y.E. is a shareholder at LifeMatrix. The other authors declare no competing interests.
Peer review information
Nature Reviews Cardiology thanks K. J. Grande-Allen, C. Simmons and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Rheumatic fever
Inflammatory disease that mostly affects children aged 5–14 years and can cause permanent damage to the heart and heart valves.
Narrowing of the heart valve, which prevents proper opening, thereby reducing the blood flow through the valve.
- Valve insufficiency
Also known as regurgitation or incompetence. Incomplete closure of the heart valve leaflets, which allows blood to flow backwards through the valve.
A procedure to tighten or reinforce the ring around a valve in the heart.
- Bi-leaflet tilting disc
A valve made of a metal ring covered by polytetrafluoroethylene, whereby the metal ring holds a disc that opens and closes after one cardiac cycle.
- Tetralogy of Fallot
A rare congenital condition caused by a combination of four heart defects: pulmonary valve stenosis, ventricular septal defect, overriding aorta and right ventricular hypertrophy.
Materials derived from tissues that originate from a different species to the recipient such as bovine pericardium or porcine valve leaflets.
- Creep resistance
Refers to a solid material’s capacity to resist creep, that is, the tendency of a solid material to move slowly or deform over long-term exposure to high levels of stress.
To deplete cells from biological tissues in order to remove DNA and immunological epitopes. Decellularization can be performed via chemical, enzymatic or physical methods to ensure a cell-free material that is available off the shelf.
To include bioactive moieties, such as proteins, peptides and polysaccharides, into a scaffold by means of covalent or non-covalent binding to improve scaffold biocompatibility.
A procedure used to reduce the diameter of the valve prosthesis by more than threefold to fit the prosthesis into the catheter used for minimally invasive implantation.
An early feasibility clinical study used to evaluate the initial clinical safety and performance in patients.
Balloon valvuloplasty or balloon valvotomy is a procedure that repairs stenotic heart valves by expanding a balloon catheter inside the valve to increase the valve opening area.
About this article
Cite this article
Fioretta, E.S., Motta, S.E., Lintas, V. et al. Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity. Nat Rev Cardiol 18, 92–116 (2021). https://doi.org/10.1038/s41569-020-0422-8
Polysaccharides, as biological macromolecule-based scaffolding systems in heart valve tissue engineering: a review
Design of a Mechanobioreactor to Apply Anisotropic, Biaxial Strain to Large Thin Biomaterials for Tissue Engineered Heart Valve Applications
Annals of Biomedical Engineering (2022)
Journal of Cardiothoracic Surgery (2021)
Pediatric Cardiology (2021)
Geometry influences inflammatory host cell response and remodeling in tissue-engineered heart valves in-vivo
Scientific Reports (2020)